[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-380379-105":59,"doc-detail-380379-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","a-review-of-10-year-survivability-of-immunotherapy-in-the-management-of-colon-cancer","A Review of 10-Year Survivability of Immunotherapy in the Management of Colon Cancer","","Colon cancer is among the most common cancers in the United States, and colorectal immunotherapy has expanded in recent years, though its clinical effectiveness remains debated. This review examines survival and progression-free rates for immunotherapy across different colorectal cancer types over the last decade, synthesizing evidence from clinical trials and studies. It highlights multiple strategies targeting growth-factor pathways (EGF, VEGF, HGF, HER2) and signaling routes (MAPK, KRAS, BRAF, PTEN), including checkpoint inhibitors such as CTLA-4 and PD-L1.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/a-review-of-10-year-survivability-of-immunotherapy-in-the-management-of-colon-cancer/380379/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/a-review-of-10-year-survivability-of-immunotherapy-in-the-management-of-colon-cancer/380379.png","ImageObject",300,407,{"name":92,"@type":93},"Aditya","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-24","2026-09-24",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What does the review evaluate regarding immunotherapy in colorectal cancer?","Question",{"text":112,"@type":113},"It investigates survival and progression-free rates of immunotherapy across different colorectal cancer types over the last 10 years.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which immunotherapy approaches are discussed as promising options?",{"text":117,"@type":113},"The review covers target therapies and adoptive cell therapy, including monoclonal antibodies against growth factors and signaling pathways, plus immune checkpoint inhibitors such as CTLA-4 and PD-L1.",{"name":119,"@type":110,"acceptedAnswer":120},"Why is immunotherapy use described as limited in colorectal cancer?",{"text":121,"@type":113},"Effectiveness is constrained by factors affecting survival and progression, including tumor microenvironment, microsatellite instability, immune checkpoint expression, and gut microbiome, along with side effects and drug-resistance mechanisms.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},380379,1790413470,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145},962085564549,"https://ap-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","Open Access Review  \nArticle DOI: 10.7759/cureus.43189  \nReceived 06/30/2023  \nReview began 07/24/2023  \nReview ended 08/04/2023  \nPublished 08/09/2023  \n© Copyright 2023  \nOkoye et al. This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 4.0. , which permits unrestricted use , distribution , and reproduction in any medium , provided the original author and source are credited.  \nA Review of 10-Year Survivability of Immunotherapy in the Management of Colon Cancer  \nChiugo Okoye 1 , My Tran 2 , Elizabeth Soladoye 3 , Darlington E. Akahara 4 , Chinemerem M. Emeasoba 5 , Blessing T. Ojinna 1 , Emmanuel Anasonye 6 , Oyindamola O. Obadare 7 , Chiamaka S. Diala 8, 3 , Bolanle H. Salaudeen 9 , Endurance O. Evbayekha 10 , Okelue E. Okobi 11, 12  \n1. Internal Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA 2. Internal Medicine, Baptist Health-University of Arkansas for Medical Sciences-Arkansas, North Little Rock, USA 3. Internal Medicine, Piedmont Athens Regional, Athens, USA 4. Medicine, Windsor University School of Medicine, Cayon, KNA 5. Internal Medicine, Imo State University, College of Medicine, Owerri, NGA 6. Internal Medicine, Texila American University, Georgetown, GUY 7. Internal Medicine, All Saints University School of Medicine, Roseau, DMA 8. Health/Biomedical Informatics, The University of Texas Health Science Center, Houston, USA 9. Internal Medicine, Lagos State University College of Medicine, Lagos, NGA 10. Internal Medicine, St. Luke 's Hospital, Chesterfield, USA  \n11. Family Medicine, Medficient Health Systems, Laurel, USA 12. Family Medicine, Lakeside Medical Center, Belle Glade, USA  \nCorresponding author: Chiugo Okoye, [thechiokoye@gmail.com](thechiokoye@gmail.com)  \nAbstract  \nColon cancer is one of the most common cancers in the United States of America. In addition to conventional treatment approaches such as surgery, chemotherapy, and radiation for colorectal cancer, immunotherapy has gained recognition over the past few years. However, its effectiveness in colorectal cancer treatment is controversial. Our study investigates the survival and progression-free rates of immunotherapy for different types of colorectal cancer over the last 10 years. We conducted literature reviews from various clinical trials and research studies to evaluate immunotherapy 's role in colorectal cancer treatment. We also investigated how it affects clinical outcomes. We discovered a range of effective immunotherapy approaches targeting various growth factors and signaling pathways. These modalities include monoclonal antibodies aimed at growth factors such as epidermal growth factor (EGF), vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF), human epidermal growth factor receptor 2 (HER2), and downstream signaling pathways such as mitogen-activated protein kinase (MAPK), kirsten rat sarcoma viral oncogene (KRAS), B-raf proto-oncogene, serine/threonine kinase (BRAF), and phosphatase and tensin homolog (PTEN) . Additionally, we identified immune checkpoint inhibitors, such as cytotoxic Tlymphocyte-associated antigen 4 (CTLA-4) inhibitors and programmed cell death ligand 1 (PD-L1)  \ninhibitors, as well as target therapy and adoptive cell therapy as promising immunotherapeutic options.  \nNevertheless, the application of immunotherapy remains highly limited due to various factors influencing survival and progression-free rates, including tumor microenvironment, microsatellite instability, immune checkpoint expression, and gut microbiome. Additionally, its effectiveness is restricted to a small subgroup of patients, accompanied by side effects and the development of drug resistance mechanisms. To unlock its full potential, further clinical trials and research on molecular pathways in colorectal cancer are imperative. This will ultimately enhance drug discovery success and lead to more effective clinical management approac","cbCaiuZtFibnqJb2","https://ap.wps.com/l/cbCaiuZtFibnqJb2","pdf",685658,15,"English","# Abstract\n## Introduction and Background","[{\"question\":\"What does the review evaluate regarding immunotherapy in colorectal cancer?\",\"answer\":\"It investigates survival and progression-free rates of immunotherapy across different colorectal cancer types over the last 10 years.\"},{\"question\":\"Which immunotherapy approaches are discussed as promising options?\",\"answer\":\"The review covers target therapies and adoptive cell therapy, including monoclonal antibodies against growth factors and signaling pathways, plus immune checkpoint inhibitors such as CTLA-4 and PD-L1.\"},{\"question\":\"Why is immunotherapy use described as limited in colorectal cancer?\",\"answer\":\"Effectiveness is constrained by factors affecting survival and progression, including tumor microenvironment, microsatellite instability, immune checkpoint expression, and gut microbiome, along with side effects and drug-resistance mechanisms.\"}]","A Review of 10-Year Survivability of Immunotherapy in the Management of Colon Cancer | PDF",1790239960,38]